Australia markets closed

SAB Biotherapeutics, Inc. (SABS)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
4.0300-0.0200 (-0.49%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.0500
Open4.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range4.0000 - 4.0000
52-week range4.0000 - 10.5000
Volume2,337
Avg. volume13,277
Market cap37.179M
Beta (5Y monthly)0.80
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    SAB Biotherapeutics Provides SAB-142 Trial Update

    MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142 with no observation of ser

  • GlobeNewswire

    SAB Biotherapeutics to Present at INNODIA Annual Meeting

    MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at t

  • GlobeNewswire

    SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

    Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the company’s Chairman and CEO, will present an overview of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 1